FDA Updates Temozolomide Prescribing Information in Brain Cancer

News
Article

Prescribing information has been updated to include temozolomide as adjuvant treatment for adult patients with newly diagnosed anaplastic astrocytoma or refractory anaplastic astrocytoma.

The updated label now includes the use of temozolomide as adjuvant treatment for adult patients with newly diagnosed anaplastic astrocytoma and for adult patients with refractory anaplastic astrocytoma.

The updated label now includes the use of temozolomide as adjuvant treatment for adult patients with newly diagnosed anaplastic astrocytoma and for adult patients with refractory anaplastic astrocytoma.

The FDA has approved updated labeling for temozolomide (Temodar) in brain cancer, according to a press release from the organization.1

The updated label now includes the use of temozolomide as adjuvant treatment for adult patients with newly diagnosed anaplastic astrocytoma and for adult patients with refractory anaplastic astrocytoma.

The press release noted that the approved indication for temozolomide in adult patients with newly diagnosed glioblastoma, given concomitantly with radiotherapy and as maintenance therapy, remains the same. Temozolomide was originally approved by the FDA under this indication in March 2005.2 Temozolomide was approved for intravenous use in 1999.3

The label update also includes the dosing regimen for patients with newly diagnosed glioblastoma and refractory anaplastic astrocytoma. For temozolomide given as capsules, there is an increase of exposure risk from opened capsules. Additionally, the patient counseling information section has been revised.

The updated labeling comes under the Project Renewal program with the Oncology Center of Excellence. This program is designed to revise label information for older drugs in the oncology space so that all information is up-to-date and relevant.

References

  1. FDA approves new and updated indications for temozolomide under Project Renewal. News release. FDA. September 14, 2023. Accessed September 14, 2023. https://bit.ly/3LnH9fS
  2. Cohen MH, Johnson JR, Pazdur R. Food and Drug Administration Ddug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res. 2005;11(19 Pt 1):6767-6771. doi:10.1158/1078-0432.CCR-05-0722
  3. Temozolomide. Prescribing information. Merck; 2023. Accessed September 14, 2023. https://bit.ly/46uUH1p
Recent Videos
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
Raymond B. Mailhot, MD, MPH, discussed how radiation therapy can impact education and survivorship for pediatric survivors of brain tumors.
Significant results from a retrospective analysis of brain tumor survivor academic performance after radiotherapy emerged despite small sampling size.
Raymond B. Mailhot, MD, MPH, discussed methods for comparing academic performances of patients following radiation therapy with healthy control groups.
The act of asking for help is critical to finding mentors who can help one advance in the brain cancer field, according to Yoshie Umemura, MD.
Through multidisciplinary collaboration, Yoshie Umemura, MD, and colleagues were able to organize the Gliofocus trial in brain cancer relatively fast.
Yoshie Umemura, MD, discusses how multiple departments can positively impact a patient with brain cancer during their visit to a medical center.
Antibody-drug conjugates and small molecule inhibitors may show utility in the neuro-oncology field, according to Nader Sanai, MD.
Related Content
Developers have requested priority review status for dordaviprone as a treatment for patients with recurrent H3 K27M-mutated glioma.

FDA Receives NDA for Dordaviprone in Recurrent H3 K27M+ Glioma

Russ Conroy
January 2nd 2025
Article

Developers have requested priority review status for dordaviprone as a treatment for patients with recurrent H3 K27M-mutated glioma.

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Forming Connections and Making a Difference in the Brain Cancer Field

Yoshie Umemura, MD
October 7th 2024
Podcast

The only way forward in the brain cancer field is to be open to mentoring others, according to Yoshie Umemura, MD.

Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells

Targeting axonal guidance dependencies in glioblastoma with ROBO1 CAR T cells

American Society for Transplantation and Cellular Therapy
November 25th 2024
Article

Researchers at SickKids Hospital and McMaster University have developed a novel CAR T-cell therapy targeting ROBO1 for the treatment of recurrent glioblastoma.

Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.

Advancing Glioblastoma Research Through a Phase 3 Niraparib Trial

Nader Sanai, MD
September 23rd 2024
Podcast

Investigators of the Gliofocus trial look to set a clinically relevant “benchmark” in the glioblastoma field, according to Nader Sanai, MD.

The developers of paxalisib will have a Type C meeting with the FDA to discuss its registration as treatment for newly diagnosed glioblastoma.

FDA Grants Type C Meeting to Discuss Paxalisib Pathways in Glioblastoma

Tim Cortese
November 7th 2024
Article

The developers of paxalisib will have a Type C meeting with the FDA to discuss its registration as treatment for newly diagnosed glioblastoma.

The FDA has set a Prescription Drug User Fee Act date of April 26, 2025, for TLX101-CDx as an imaging agent for patients with glioma.

PET Imaging Agent Earns FDA Priority Review in Recurrent Glioma

Russ Conroy
October 25th 2024
Article

The FDA has set a Prescription Drug User Fee Act date of April 26, 2025, for TLX101-CDx as an imaging agent for patients with glioma.